Alza Concerta
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
>Once-daily methylphenidate receives approval Aug. 1 for pediatric attention deficit/hyperactivity disorder. Concerta is slated for an August launch, coinciding with the start of the school year, according to Alza and co-marketing partner McNeil Consumer Healthcare. A combined sales force of 520 reps will promote Concerta. The product will be launched at a wholesale acquisition cost of $1.75 per tablet for the 18 mg dose and $1.85 per tablet for the 36 mg dose, which represents a 71¢ to 81¢ discount to the daily cost of Novartis' twice-daily Ritalin-SR
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.